Asprosin in early detection of nephropathy in type2 diabetes mellitus

Abstract

Abstract Background: Diabetic nephropathy (DN) accounts for the most prevalent cause of chronic kidney disease and end-stage renal disease (ESRD) globally, accounting for about 50% of all ESRD patients that need management with dialysis or a renal transplant. Objectives: The aim of this study was to the role of Asprosin as an independent and trustworthy biomarker for the quick diagnosis of DN by knowing the sensitivity and specificity, acceptable to add to the diagnostic protocol. Evaluated fasting blood glucose asprosin, lipid profile, urea, creatinine, and albumin levels in apparently healthy groups, diabetic groups, and diabetic groups with nephropathy to determine their medical significance; asprosin can be used as an independent and trustworthy biomarker for the quick diagnosis of DN by knowing the sensitivity and specificity, acceptable to add to the diagnostic protocol. Materials and Methods: Blood samples were obtained from the Diabetes and Endocrine Center in Hilla city, Babylon province’s Marjan Medical City, from October 25, 2021 to January 31, 2022. Sixty type 2 diabetes mellitus (T2DM) patients were classified into 30 with diabetes mellitus, 30 with DN, and 30 apparently healthy patients. Serum asprosin levels were measured using a commercial enzyme-linked immunosorbent assay kit. SPSS software was used to conduct the statistical analysis. Results: Both T2DM patients with and without nephropathy had considerably higher levels of fasting blood glucose (FBG), asprosin, serum urea, creatinine, total cholesterol, triglyceride (TG), low-density lipoprotein cholesterol, and very low-density lipoprotein cholesterol compared to the healthy appearance group, although both groups had significantly lower levels of albumin and high-density lipoprotein cholesterol (HDL-C). Asprosin additionally showed a positively correlated with serum urea, TG, and HDL-C and shown negative correlation with serum albumin. The sensitivity and specificity of the test at the cut-off value of asprosin 17.5 ng/mL were 86.7% and 80%, respectively, and the area under the curve was 0.92, P-value = 0.001. Conclusion: Because blood asprosin levels have a sensitivity and specificity of more than 80% in T2DM patients with nephropathy, they can be used as an independent and trustworthy biomarker for the quick diagnosis of DN.